Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295817452> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W4295817452 endingPage "S732" @default.
- W4295817452 startingPage "S732" @default.
- W4295817452 abstract "Presence of extramural venous invasion (EMVI) by magnetic resonance imaging (MRI) is an independent poor prognostic factor in locally advanced rectal cancer (LARC). Nevertheless, the efficacy of both pre-neoadjuvant therapy (NAT) and post-NAT MRI EMVI assessment to predict pathological response and long-term benefit (in terms of disease-free survival (DFS) and overall survival (OS) has not been clearly established. We analyzed 239 patients with LARC receiving NAT with continuous infusion fluorouracil (n=229) or capecitabine (n=10) diagnosed between 2009 and 2019. Baseline and post-NAT MRI EMVI status was assessed in 214 and 173 patients respectively by two radiologists with more than 20-year and 5-year experience. When discrepancies, EMVI status was decided by consensus. Post-surgical pathologic assessment detached good-responders (ypT0N0 and ypT1-2N0) from poor-responders (ypT3Nx or ypTxN1/2). Three-year DFS and 5-year OS were estimated using Kaplan-Meier product-limit method. Baseline EMVI positive (91/214; 42%) was significantly associated with poor pathological response (74/91; 81%) vs. EMVI negative (52/123; 43%), p=0.0001. In the subset of patients evaluated with pre and post MRI, 69/173 (40%) presented positive EMVI at baseline. 21/69 (30%) patients with positive baseline EMVI became negative after therapy (EMVI (+/-)). Three-year DFS was 80.9% in EMVI (-/-), 66.7% in EMVI (+/-), and 45.2% in EMVI (+/+), HR 1.84 (95% CI 1.38-2.44), p=0.000026. Five-year OS was 82.6%, 73.9% and 57.3%, respectively, with HR 1.67 (95% CI 1.26-2.23), p=0.0004. Baseline EMVI accurately predicted pathological efficacy after conventional NAT. Patients that negativized EMVI (+/-) showed significantly better DFS and OS compared to patients that remained positive EMVI (+/+)." @default.
- W4295817452 created "2022-09-15" @default.
- W4295817452 creator A5000353184 @default.
- W4295817452 creator A5001839448 @default.
- W4295817452 creator A5002252359 @default.
- W4295817452 creator A5008921748 @default.
- W4295817452 creator A5009894963 @default.
- W4295817452 creator A5011249857 @default.
- W4295817452 creator A5020633136 @default.
- W4295817452 creator A5029625883 @default.
- W4295817452 creator A5050829623 @default.
- W4295817452 creator A5055468712 @default.
- W4295817452 creator A5055621873 @default.
- W4295817452 creator A5070871701 @default.
- W4295817452 creator A5073126802 @default.
- W4295817452 creator A5080761742 @default.
- W4295817452 creator A5089785923 @default.
- W4295817452 creator A5090685909 @default.
- W4295817452 date "2022-09-01" @default.
- W4295817452 modified "2023-10-18" @default.
- W4295817452 title "433P Pre-treatment and post-treatment MRI extramural venous invasion, predicts disease-free survival and overall survival, in locally advanced rectal cancer" @default.
- W4295817452 doi "https://doi.org/10.1016/j.annonc.2022.07.571" @default.
- W4295817452 hasPublicationYear "2022" @default.
- W4295817452 type Work @default.
- W4295817452 citedByCount "0" @default.
- W4295817452 crossrefType "journal-article" @default.
- W4295817452 hasAuthorship W4295817452A5000353184 @default.
- W4295817452 hasAuthorship W4295817452A5001839448 @default.
- W4295817452 hasAuthorship W4295817452A5002252359 @default.
- W4295817452 hasAuthorship W4295817452A5008921748 @default.
- W4295817452 hasAuthorship W4295817452A5009894963 @default.
- W4295817452 hasAuthorship W4295817452A5011249857 @default.
- W4295817452 hasAuthorship W4295817452A5020633136 @default.
- W4295817452 hasAuthorship W4295817452A5029625883 @default.
- W4295817452 hasAuthorship W4295817452A5050829623 @default.
- W4295817452 hasAuthorship W4295817452A5055468712 @default.
- W4295817452 hasAuthorship W4295817452A5055621873 @default.
- W4295817452 hasAuthorship W4295817452A5070871701 @default.
- W4295817452 hasAuthorship W4295817452A5073126802 @default.
- W4295817452 hasAuthorship W4295817452A5080761742 @default.
- W4295817452 hasAuthorship W4295817452A5089785923 @default.
- W4295817452 hasAuthorship W4295817452A5090685909 @default.
- W4295817452 hasConcept C121608353 @default.
- W4295817452 hasConcept C126322002 @default.
- W4295817452 hasConcept C126838900 @default.
- W4295817452 hasConcept C143409427 @default.
- W4295817452 hasConcept C143998085 @default.
- W4295817452 hasConcept C207886595 @default.
- W4295817452 hasConcept C526805850 @default.
- W4295817452 hasConcept C71924100 @default.
- W4295817452 hasConceptScore W4295817452C121608353 @default.
- W4295817452 hasConceptScore W4295817452C126322002 @default.
- W4295817452 hasConceptScore W4295817452C126838900 @default.
- W4295817452 hasConceptScore W4295817452C143409427 @default.
- W4295817452 hasConceptScore W4295817452C143998085 @default.
- W4295817452 hasConceptScore W4295817452C207886595 @default.
- W4295817452 hasConceptScore W4295817452C526805850 @default.
- W4295817452 hasConceptScore W4295817452C71924100 @default.
- W4295817452 hasLocation W42958174521 @default.
- W4295817452 hasOpenAccess W4295817452 @default.
- W4295817452 hasPrimaryLocation W42958174521 @default.
- W4295817452 hasRelatedWork W2049214470 @default.
- W4295817452 hasRelatedWork W2324781352 @default.
- W4295817452 hasRelatedWork W2352753275 @default.
- W4295817452 hasRelatedWork W2367942071 @default.
- W4295817452 hasRelatedWork W2370951652 @default.
- W4295817452 hasRelatedWork W2371062916 @default.
- W4295817452 hasRelatedWork W2392730113 @default.
- W4295817452 hasRelatedWork W2902148150 @default.
- W4295817452 hasRelatedWork W3004259476 @default.
- W4295817452 hasRelatedWork W3039284339 @default.
- W4295817452 hasVolume "33" @default.
- W4295817452 isParatext "false" @default.
- W4295817452 isRetracted "false" @default.
- W4295817452 workType "article" @default.